Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-462795 versus alendronate and placebo in postmenopausal osteoporosis
2006-000635-94Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Relacatib in osteoporosis (6 arms), sponsored by GSK. Primary endpoint: Change from baseline lumbar spine BMD at Month 12. Started Apr 2006; status: completed.
02
Drugs
Relacatib
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2006-000635-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000635-94.